Hepatocellular carcinoma (HCC) imposes a major health and economic burden worldwide, with disproportionate effects in low- and middle-income countries (LMICs). Surveillance in high-risk populations, typically using semiannual ultrasound and alpha-fetoprotein testing, has been shown to be cost-effective by enabling earlier detection and improving survival. Yet, its overall value is reduced by poor adherence and the limited sensitivity of ultrasound, particularly in patients with metabolic-associated steatotic liver disease. Emerging approaches—including abbreviated magnetic resonance imaging, multi-biomarker models (e.g., gender, age, AFP, AFP-L3, and DCP), and liquid biopsy assays such as methylated DNA markers—demonstrate greater diagnostic accuracy and potential economic advantages compared with conventional methods. Integration of artificial intelligence into imaging may further enhance efficiency and reduce downstream costs. Moving toward precision surveillance, guided by individualized risk stratification that incorporates etiology, fibrosis stage, and molecular profiles, can optimize allocation of resources and maximize cost-effectiveness at the population level. Interventions to improve adherence, including mailed outreach and behavioral economic incentives, have shown both clinical benefit and cost savings, underscoring the role of implementation science. Because socioeconomic disparities influence both access and outcomes, economic models must explicitly address equity to achieve sustainable impact. Future research should prioritize prospective trials that evaluate not only clinical performance but also the real-world cost-effectiveness of novel technologies and stratified surveillance strategies. For LMICs, adapting proven models into affordable, context-appropriate programs is essential. By combining prevention, precision risk assessment, innovative technologies, and equitable implementation, HCC surveillance can deliver both clinical and economic value, reducing the global burden of disease.
Citations
Citations to this article as recorded by
Toward Precise Risk Stratification after the Functional Cure of Chronic Hepatitis B Moon Haeng Hur The Korean Journal of Gastroenterology.2026; 86(2): 71. CrossRef
Burden and Regional Disparities of MASH‐Related Liver Cancer in the Asia‐Pacific Region From 1990 to 2023 Xiao‐Dong Zhou, Qin‐Fen Chen, Daniel Q. Huang, Hung N. Luu, Giovanni Targher, Christopher D. Byrne, Huai Zhang, Mazen Noureddin, Renyi Su, Jacob George, Zobair M. Younossi, Frank Tacke, Ming‐Hua Zheng Liver International.2026;[Epub] CrossRef
Background/Aims The first metabolic dysfunction-associated steatotic liver disease (MASLD) drug was approved with an unsatisfactorily small effect size. This study aimed to determine key factors impacting the cost-effectiveness of a new hypothetical MASLD drug as well as its treatment efficacy.
Methods A Markov model reflecting the natural history of MASLD was developed, incorporating fibrosis progression, cardiovascular disease risk, and mortality. Treatment effect of drug X (with $20,000 of annual cost) was assumed to achieve a ≥1 stage fibrosis regression, with a 25% gap of effect size in regression rate over non-treatment in the first year. The incremental cost-effectiveness ratio (ICER) over a 20-year horizon was estimated. And sensitivity analyses were conducted to explore uncertainty and identify influential factors.
Results In the base case analysis, drug X provided an incremental gain of 1.32 quality-adjusted life years (QALYs) and 1.20 life years compared to the non-treatment, with an ICER of $68,010/QALY–below the $100,000/QALY willingnessto- pay threshold, indicating that drug X treatment is cost-effective. Two-way sensitivity analysis further highlighted that the drug should achieve at least a 15% initial regression gap and maintain a minimum 3% sustained durability gap to remain cost-effective. In addition baseline fibrosis stage distribution also acted as an influencing factor.
Conclusions Long-term sustained durability of the hypothetical drug, patient distribution based on baseline fibrosis stage, as well as initial treatment response rate are key factors that influence the cost-effectiveness of new MASLD drugs.
Citations
Citations to this article as recorded by
The MASLD Journey in the General Population: Linkage‐to‐Care and Patient‐Reported Uptake of Fibrosis Risk Assessment Joo Hyun Oh, Jun‐Hyuk Lee, Sang Bong Ahn, Eunjoo Kwon, Eileen L. Yoon, Hyo Young Lee, Seon Cho, Dae Won Jun Liver International.2026;[Epub] CrossRef
Hepatocellular carcinoma surveillance: a health economic evaluation Qi-Feng Chen, Xiong-Ying Jiang, Song Chen, Jiongliang Wang, Ming Zhao Clinical and Molecular Hepatology.2026; 32(2): 536. CrossRef
Background/Aims The World Health Organization set the goal of eliminating hepatitis C virus (HCV) by 2030, with 80% and 65% reductions in HCV incidence and mortality rates, respectively. We aimed to evaluate the health benefits, cost-effectiveness and return on investment (ROI) of HCV elimination.
Methods Using an HCV transmission compartmental model, we evaluated the benefits and costs of different strategies combining screening and treatment for Chinese populations. We identified strategies to achieve HCV elimination and calculated the incremental cost-effectiveness ratios (ICERs) per disability-adjusted life year (DALY) averted for 2022–2030 to identify the optimal elimination strategy. Furthermore, we estimated the ROI by 2050 by comparing the required investment with the economic productivity gains from reduced HCV incidence and deaths.
Results The strategy that results in the most significant health benefits involves conducting annual primary screening at a rate of 14%, re-screening people who inject drugs annually and the general population every five years, and treating 95% of those diagnosed (P14-R4-T95), preventing approximately 5.75 and 0.44 million HCV infections and deaths, respectively, during 2022–2030. At a willingness-to-pay threshold of $12,615, the P14-R4-T95 strategy is the most cost-effective, with an ICER of $5,449/DALY. By 2050, this strategy would have a net benefit of $120,997 million (ROI=0.868).
Conclusions Achieving HCV elimination in China by 2030 will require significant investment in large-scale universal screening and treatment, but it will yield substantial health and economic benefits and is cost-effective.
Citations
Citations to this article as recorded by
Overcoming barriers to HCV screening in Latin America: From evidence to action Javier Crespo, Jose Luis Calleja, Ezequiel Ridruejo, Marta Alonso-Peña, Joaquín Cabezas, Graciela Elia Castro-Narro, Nelia Hernandez, Hugo Cheinquer, Fernando Contreras, Christie Perelló, Manuel Mendizabal, Fernando Cairo, Mário Guimarães Pessôa, Eduardo Annals of Hepatology.2026; 31(2): 102189. CrossRef
Global Advances in Hepatocellular Carcinoma Research and Therapy in 2025 Bo Hu, Qiang Gao Cancer Innovation.2026;[Epub] CrossRef
Evaluation of the performance of reverse transcription-recombinase polymerase amplification (RT-RPA) coupled with CRISPR/Cas12a and microfluidics for one-step detection of common HCV genotypes Qiong Wang, Yushu Wang, Tian Jia, Xiaodong Hu, Fuliang Chen Diagnostic Microbiology and Infectious Disease.2026; 116(3): 117482. CrossRef
Burden and Long-Term Trends of Viral Hepatitis in China: A National and Provincial Analysis Jing-yi Peng, Xin-yu Xiang, Jie Zhang, Yuan Yuan, Yang Ding, Yu-chen Xia, You-de Xiao, Xing-xing He Current Medical Science.2026; 46(3): 828. CrossRef
Cost-Effectiveness of Screening and Treating Chronic Hepatitis C Virus Infection in Zimbabwe Blessing Dzingirai, Leolin Katsidzira, Maarten J. Postma, Marinus van Hulst, Nyashadzaishe Mafirakureva International Journal of Environmental Research and Public Health.2025; 22(4): 509. CrossRef
Investing in health: Policy lessons from reimbursing direct-acting antivirals for hepatitis C in Taiwan Raoh-Fang Pwu, Wen-Wen Yang, Grace Hui-Min Wu, Sheng-Nan Lu, Rong-Nan Chien Journal of the Formosan Medical Association.2025; 124: S141. CrossRef
HCV self-testing: Bridging screening gaps and ensuring cost-effectiveness for both high-risk and universal populations: Correspondence to editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of dis Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn Clinical and Molecular Hepatology.2025; 31(2): e163. CrossRef
Background/Aims The World Health Organization (WHO) aims to eliminate hepatitis C virus (HCV) by 2030; therefore, widespread HCV screening is required. The WHO recommends HCV self-testing (HCVST) as a new approach. We aimed to evaluate disease burden reduction using the HCVST screening strategy and identify the most cost-effective approach.
Methods We developed a dynamic open-cohort Markov model to assess the long-term effects and costeffectiveness of HCVST in the Republic of Korea from 2024 to 2030. Strategies for comparison included universal, birth cohort, high-risk group screening, and no screening, focusing on the following: (1) incremental costeffectiveness ratio (ICER) per disability-adjusted life-year (DALY) saved; (2) severe liver disease cases; and (3) liverrelated death reduction.
Results Universal HCVST screening is the most effective strategy for achieving the WHO goal by 2030, substantially lowering the incidence of severe liver disease by 71% and preventing liver-related deaths by 69%, thereby averting 267,942 DALYs. Moreover, with an ICER of US$8,078 per DALY and high cost-effectiveness, the sensitivity results prove that cost-effectiveness is robust. Although high-risk group screening offers the lowest cost compared with other strategies, its effectiveness in preventing severe liver disease is minimal, falling short of the current WHO goal.
Conclusions Our study confirms that universal HCVST screening is a cost-effective strategy aligned with the WHO goal to eliminate HCV by 2030. Despite its higher costs compared to risk-based screening, the disease burden can be significantly reduced by providing effective HCVST access to individuals who might otherwise not be tested.
Citations
Citations to this article as recorded by
Acceptability and Usability of Blood-Based and Oral Fluid HCV Self-Testing Among Men-Who-Have-Sex-with-Men and Transgender Women on PrEP Hugo Perazzo, Sandra W. Cardoso, Thiago S. Torres, Daniel Bezerra, Ketiuce Zukeram, Marcos Benedetti, Julio Moreira, Brenda Hoagland, Cristina Pimenta, Beatriz Grinsztejn, Valdilea G. Veloso AIDS and Behavior.2026;[Epub] CrossRef
HCV self-testing: Bridging screening gaps and ensuring cost-effectiveness for both high-risk and universal populations: Correspondence to editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of dis Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn Clinical and Molecular Hepatology.2025; 31(2): e163. CrossRef
Universal self-testing as a cost-effective weapon to eliminate hepatitis C virus in the Republic of Korea: Editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiven Eun Sun Jang Clinical and Molecular Hepatology.2025; 31(2): 596. CrossRef
Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study Meiyu Wu, Jing Ma, Xuehong Wang, Sini Li, Chongqing Tan, Ouyang Xie, Andong Li, Aaron G Lim, Xiaomin Wan Clinical and Molecular Hepatology.2025; 31(2): 394. CrossRef
Future Perspectives of Liver Research in the Asia‐Pacific Region: Focus on Hepatitis B and C Beom Kyung Kim Journal of Gastroenterology and Hepatology.2025; 40(8): 1855. CrossRef
Bridging the Gap in Elimination of Hepatitis C Virus among People Who Use Drugs in South Korea Beom Kyung Kim Gut and Liver.2025; 19(5): 635. CrossRef
OraQuick hepatitis C virus self-test: A new frontier in hepatitis C screening Muneeb Saifullah, Mavra Khan, Muhammad Ashhad Usman, Qasim Mehmood, Abbas M Mehdi World Journal of Virology.2025;[Epub] CrossRef
Hepatitis C virus (HCV) infection is the second most common cause of chronic liver disease in South Korea, with a prevalence ranging from 0.6% to 0.8%, and HCV infection incidence increases with age. The anti-HCV antibody test, which is cheaper than the HCV RNA assay, is widely used to screen for HCV infections; however, the underdiagnosis of HCV is a major barrier to the elimination of HCV infections. Although several risk factors have been associated with HCV infections, including intravenous drug use, blood transfusions, and hemodialysis, most patients with HCV infections present with no identifiable risk factors. Universal screening for HCV in adults has been suggested to improve the detection of HCV infections. We reviewed the cost-effectiveness of HCV screening and the methodologies used to perform screening. Recent studies have suggested that universal HCV screening and treatment using direct-acting antivirals represent cost-effective approaches to the prevention and treatment of HCV infection. However, the optimal timing and frequency of HCV screening remain unclear, and further studies are necessary to determine the best approaches for the elimination of HCV infections.
Citations
Citations to this article as recorded by
Trends and health inequalities of hepatitis virus-associated liver cancer mortality during 1990–2050 Yujiao Deng, Jingyue Tan, Jian Zu, Zixuan Xing, Zhanpeng Yang, Yue Zhang, Yajing Bo, Xu Gao, Enrui Xie, Yuan Wang, Meijuan Han, Fanpu Ji, Yang Yang Annals of Hepatology.2026; 31(1): 102144. CrossRef
Implementation of an alert system for the care cascade of Hepatitis C infection in patients undergoing elective surgery Jae Seung Lee, Ho Soo Chun, Hye Won Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Journal of Infection and Public Health.2026; 19(2): 103076. CrossRef
Outcomes of Highly Urgent ABO-Incompatible Living Donor Liver Transplantation in National Databases Jongman Kim, Sang Jin Kim, Boram Park, Kyunga Kim, YoungRok Choi, Geun Hong, Jun Yong Park, Young Seok Han, Nam-Joon Yi, Seung Heui Hong, Soon-Young Kim, Jungbun Park, Youngwon Hwang, Dong-Hwan Jung Journal of Korean Medical Science.2026;[Epub] CrossRef
Lessons learned from viral hepatitis testing that inform law and policy responses to steatotic liver disease Jeffrey V. Lazarus, Christopher J. Kopka, Aina Nicolàs, Safura Abdool Karim, Meena B. Bansal, Michael Betel, John F. Dillon, Pere Gines, Aleksander Krag, Veronica Miller, Cynthia A. Moylan, Alisa Pedrana, Paula Petrone, Jörn M. Schattenberg, Sunil S. Solo Nature Reviews Gastroenterology & Hepatology.2026; 23(4): 355. CrossRef
Impact of sustained virological response on prognosis after hepatectomy for hepatitis C-related hepatocellular carcinoma: a retrospective cohort study Pei-shu Li, Guo-dong Yang, Xiu-nan Huang, Xin-yuan Wu, Yi-fan Li, Ming-jian Huang, Jie Zhang, Bang-de Xiang BMC Infectious Diseases.2026;[Epub] CrossRef
HCV self-testing: Bridging screening gaps and ensuring cost-effectiveness for both high-risk and universal populations: Correspondence to editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of dis Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn Clinical and Molecular Hepatology.2025; 31(2): e163. CrossRef
Predicting hepatitis C infection via machine learning Yueyue Zhu American Journal of Translational Research.2025; 17(7): 5120. CrossRef
Longitudinal Effects of Glecaprevir/Pibrentasvir on Liver Function, Fibrosis, and Hepatocellular Carcinoma Risk in Chronic Hepatitis C: A Prospective Multicenter Cohort Study Jung Hee Kim, Jae Hyun Yoon, Sung-Eun Kim, Ji-Won Park, Yewan Park, Gi-Ae Kim, Seong Kyun Na, Young-Sun Lee, Jeong Han Kim Medicina.2025; 61(9): 1601. CrossRef
Predicting risk factors for waiting mortality in adult emergent living donor liver transplantation based on Korean national data Sang Jin Kim, Jongman Kim, Kyunga Kim, Soon-Young Kim, Jung-Bun Park, Youngwon Hwang, Dong-Hwan Jung Annals of Liver Transplantation.2025; 5(2): 107. CrossRef
Chronic viral hepatitis C micro‐elimination program using telemedicine in Guigang city Riying Lv, Yanmeng Lu, Wenyao Xiang, Menglan Meng, Shixiong Li Journal of Viral Hepatitis.2024; 31(4): 208. CrossRef
Hepatitis C virus infection in patients undergoing surgery in a single tertiary academic center Jae Seung Lee, Hye Won Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim Journal of Gastroenterology and Hepatology.2024; 39(6): 1155. CrossRef
Toward hepatitis C virus elimination using artificial intelligence Moon Haeng Hur, Jeong-Hoon Lee Clinical and Molecular Hepatology.2024; 30(2): 147. CrossRef
Contemporary Insights into Hepatitis C Virus: A Comprehensive Review Malik Sallam, Roaa Khalil Microorganisms.2024; 12(6): 1035. CrossRef
Prognosis Following Sustained Virologic Response in Korean Chronic Hepatitis C Patients Treated with Sofosbuvir-Based Treatment: Data from a Multicenter Prospective Observational Study up to 7 Years Yewan Park, Seong-Kyun Na, Jae-Hyun Yoon, Sung-Eun Kim, Ji-Won Park, Gi-Ae Kim, Hyo-Young Lee, Young-Sun Lee, Jeong-Han Kim Medicina.2024; 60(7): 1132. CrossRef
An ultrasensitive fluorescence sensing platform for HCV detection based on the T7 isothermal amplification combined with aggregation-induced emission luminogens strategy Wuxiu Guo, Xin Zhu, Jinchao Li, Linhai Li Sensors and Actuators Reports.2024; 8: 100229. CrossRef
Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus: A systematic review and meta-analysis Han Ah Lee, Mi Na Kim, Hye Ah Lee, Miyoung Choi, Jung Hwan Yu, Young-Joo Jin, Hee Yeon Kim, Ji Won Han, Seung Up Kim, Jihyun An, Young Eun Chon Clinical and Molecular Hepatology.2024; 30(Suppl): S172. CrossRef
Quality Assurance for Hepatitis C Virus Point-of-Care Diagnostics in Sub-Saharan Africa Evans Duah, Evans Mantiri Mathebula, Tivani Mashamba-Thompson Diagnostics.2023; 13(4): 684. CrossRef
Response to antiviral therapy for chronic hepatitis C and risk of hepatocellular carcinoma occurrence in Japan: a systematic review and meta-analysis of observational studies Yoko Yamagiwa, Keitaro Tanaka, Keitaro Matsuo, Keiko Wada, Yingsong Lin, Yumi Sugawara, Tetsuya Mizoue, Norie Sawada, Hidemi Takimoto, Hidemi Ito, Tetsuhisa Kitamura, Ritsu Sakata, Takashi Kimura, Shiori Tanaka, Manami Inoue, Sarah Krull Abe, Shuhei Nomur Scientific Reports.2023;[Epub] CrossRef
Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study Chang Hun Lee, Gwang Hyeon Choi, Hwa Young Choi, Sojung Han, Eun Sun Jang, Young Eun Chon, Young Chang, Kyung-Ah Kim, Do Young Kim, Hyung Joon Yim, Hye-Lin Kim, Sook-Hyang Jeong, In Hee Kim Clinical and Molecular Hepatology.2023; 29(3): 779. CrossRef
Prognosis of Patients with Chronic Hepatitis C Genotype 1b Infection Treated Using Daclatasvir/Asunaprevir after Sustained Virologic Response: A 6-Year Multicenter Prospective Observational Study Jae-Hyun Yoon, Sung-Eun Kim, Su-Hyeon Cho, Gi-Ae Kim, Yewan Park, Ji-Won Park, Seong-Hee Kang, Young-Sun Lee, Jeong-Han Kim Medicina.2023; 59(8): 1436. CrossRef
Burden of liver cancer due to hepatitis C from 1990 to 2019 at the global, regional, and national levels Jie Wei, Guoqing Ouyang, Guozhen Huang, Yong Wang, Shuangjiang Li, Jiaping Liu, Yanhong Zhang, Guandou Yuan, Songqing He Frontiers in Oncology.2023;[Epub] CrossRef
Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study Soon Kyu Lee, Sung Won Lee, Hae Lim Lee, Hee Yeon Kim, Chang Wook Kim, Do Seon Song, U Im Chang, Jin Mo Yang, Sun Hong Yoo, Jung Hyun Kwon, Soon Woo Nam, Seok-Hwan Kim, Myeong Jun Song, Jaejun Lee, Hyun Yang, Si Hyun Bae, Ji Won Han, Heechul Nam, Pil Soo The Korean Journal of Internal Medicine.2022; 37(6): 1167. CrossRef
First
Prev
